Steven Quayle
Senior Vice President & Head of Research & Translational Medicine Cue Biopharma
Steven Quayle, PhD, is Senior Vice President and Head of Research and Translational Medicine at Cue Biopharma, where he leads the discovery and development of precision immunotherapeutics. Since joining Cue in 2017, he has advanced novel biologics for antigen-specific T-cell modulation across research and clinical programs. Previously, Dr. Quayle held leadership roles in oncology and translational biology at KDAc Therapeutics and Acetylon Pharmaceuticals and conducted postdoctoral research at Dana-Farber Cancer Institute. He earned his PhD in Pathology and Laboratory Medicine and his BSc in Cell Biology from the University of British Columbia, focusing on cancer biology and immunology.
Seminars
- Highlighting the key considerations guide indication selection for Treg therapies
- Exploring the success of antigen specific Treg trafficking to key disease areas to effectively evaluate treatment efficacy and guide indication selection
- Assessing opportunities for leveraging Treg bystander effects to enhance immune modulation across multiple conditions
- Considering how preclinical model availability influences indication strategies, from narrow focus to broader applications
